Veoza Approved for Use in England
Veoza (fezolinetant) has been officially approved for use on the NHS to prevent hot flushes in menopausal women. This significant development is expected to benefit around 500,000 women in England who experience these symptoms, which affect approximately 70% of women undergoing menopause.
Details of the Treatment
The treatment is administered as a once-daily oral tablet, providing a convenient option for women. Veoza works by blocking nerve pathways in the brain that trigger hot flushes and night sweats, offering a new mechanism of action compared to traditional hormone replacement therapy (HRT).
Target Audience and Cost
Veoza is specifically intended for women for whom HRT is unsuitable, addressing a long-standing gap in treatment options. The NHS list price for Veoza is £44.80 per 28-tablet pack, a cost that has been deemed reasonable by the National Institute for Health and Care Excellence (NICE), which found the drug to be cost-effective and valuable for taxpayers.
Expert Opinions
Health experts have welcomed this approval, emphasizing the importance of addressing menopausal symptoms. Helen Knight, a spokesperson for NICE, stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She added, “This decision will give much-needed relief to those for whom HRT is unsuitable.”
Impact on Women’s Health
Dr. Sue Mann also expressed her support, noting, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She further highlighted that Veoza represents another vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.
For decades, there have been few safe and effective treatment options for menopausal hot flushes, making the approval of Veoza a noteworthy advancement in women’s health. The introduction of this drug marks a significant step forward in providing alternatives for women seeking relief from menopausal symptoms.
Future Expectations
As Veoza becomes available, healthcare providers and patients alike are optimistic about its potential to improve the quality of life for many women. However, details remain unconfirmed regarding the broader rollout and accessibility of the drug across different regions in England.